Role of gene therapy in tissue engineering procedures in rheumatology: the use of animal models
Source abstract
Abstract
Tissue engineering is not only the application of cells and scaffolds to generate a new tissue but should also bring into play biological principles to guide cellular behavior. A way to modify cellular behavior is genetic modification of the cells used for tissue engineering (gene therapy). In the field of rheumatic diseases, cellular modification by overexpressing anabolic factors, such as insulin-like growth factor-I or transforming growth factor beta, or inhibitors of catabolic cytokines or proteolytic enzymes can protect tissues form further destruction and stimulate tissue repair. To test the effect of transgenes on tissue engineering adequate test systems have to be available. Initial testing can be done in simple in vitro systems. However, animal models are unavoidable to study the interaction between the environment and tissue engineering. Optimal models to study gene therapy in combination with tissue engineering in the field of rheumatology are not available at this moment. Arthritis models are mainly developed in small animals while high-quality tissue engineering experiments ask for a large animal model. Development of animal models that can be used for tissue engineering experiments and mimic end stage arthritic diseases is needed.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Virus-based gene therapy research · Mesenchymal stem cell research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (59)
Show source-provided references
1. Immunopathogenesis of rheumatoid arthritis
2. Osteoarthritis
3. Anticytokine treatment of established collagen-induced arthritis in DBA/I mice. A comparative study using anti-TNFα, antiIL-1α/β, and IL-1RA10.1002/art.1780390513 ↗
4. Amelioration of established murine collagen induced arthritis witj antiIL-1 treatment10.1111/j.1365-2249.1994.tb06517.x ↗
5. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis10.1073/pnas.89.20.9784 ↗
6. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice10.4049/jimmunol.151.11.6602 ↗
7. Different roles of TNFα and IL-1 in murine streptococcal cell wall arthritis10.1006/cyto.1998.0372 ↗
8. Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis10.1002/art.1780380204 ↗
9. Suppression of antigen-induced arthritis by gene therapy10.4049/jimmunol.156.9.3558 ↗
10. Autoimmunity to type II collagen10.1084/jem.146.3.857 ↗
11. Prevention of murine collagen-induced arthritis in the knee and ipsilatral paw by local expression of human interleukin-1 receptor antagonist protein in the knee10.1002/art.1780400517 ↗
12. C3-tat/HIV regulated intraarticular human IL-1 receptor antagonist gene therapy results in efficient inhibition of collagen-induced arthritis superior to CMV-regulated expression of the same transgene10.1002/art.10481 ↗
13. Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis10.4049/jimmunol.163.2.1000 ↗
14. The type I IL-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice10.1002/eji.1830250647 ↗
15. Direct gene delivery strategies for the treatment of rheumatoid arthritis10.1016/S1359-6446(01)01685-3 ↗
16. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction10.4049/jimmunol.163.8.4546 ↗
17. Systemic viral interleukin-10 gene delivery prevents cartilage invasion by human rheumatoid synovial tissue engrafted in SCID mice10.1002/1529-0131(199904)42:4<678::AID-ANR10>3.0.CO;2-S ↗
18. Gene transfer of cytokine inhibibitors into human synovial fibroblasts in the SCID mouse model10.1002/1529-0131(199904)42:3<490::AID-ANR14>3.0.CO;2-L ↗
19. Inhibition of cartilage destruction by double gene transfer of IL-1RA and IL-10 involves the activin pathway10.1038/sj.gt.3301811 ↗
20. Interleukin-13 gene therapy reduces inflammation, vascularization, and bony destruction in rat adjuvant-induced artrhritis10.1089/10430340252792512 ↗
21. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor κB decoy oligonucleotides as a gene therapy10.1002/1529-0131(199912)42:12<2532::AID-ANR5>3.0.CO;2-2 ↗
22. Inhibitor of nuclear factor κB kinase beta is a key regulator of synovial uinflammation10.1002/1529-0131(200108)44:8<1897::AID-ART328>3.0.CO;2-4 ↗
23. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene tranfer of a cell surface-targeted plasmin inhibitor10.1002/1529-0131(200008)43:8<1710::AID-ANR6>3.0.CO;2-Y ↗
24. Adenovirus-based issue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice10.1002/1529-0131(200112)44:12<2888::AID-ART477>3.0.CO;2-3 ↗
25. Paradoxical effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis10.1002/1529-0131(200106)44:6<1444::AID-ART240>3.0.CO;2-Q ↗
26. Adenovirus-mediated gene transfer of insulin-like growth factor-I stimulates proteoglycan synthesis in rabbit joints10.1002/1529-0131(200011)43:11<2563::AID-ANR25>3.0.CO;2-8 ↗
27. Differential effects of local application of BMP-2 or TGF-β on both articular cartilage composition and osteophyte formation10.1053/joca.1998.0129 ↗
28. Stimulation of articular cartilage repair in established arthyritis by local administration of transforming growth factor β into murine knee joints
29. Overexpression of active TGF β1 in the murine knee joint. Evidence for synovial layer dependent chondro-osteophyte formation10.1053/joca.2000.0368 ↗
30. In vivo protection against interleukin-1-induced articular cartilage damage by transforming growth factor-β110.1136/ard.53.9.593 ↗
31. BMP-2 stimulates articular proteoglycan synthesis in vivo but is not able to counteract IL-1 effects on proteoglycan synthesis and content10.1002/art.1780400605 ↗
32. Role of nitric oxide in the inhibition of BMP-2-mediated stimulation of proteoglycan synthesis in articular cartilage10.1053/joca.1999.0275 ↗
33. BMP-2 and BMP-9 promotes chondrogenic differentiation of human multipotential mesenchymal cells and overcomes the inhibitory effect of IL-110.1002/jcp.10025 ↗
34. Differential effects of local application of BMP-2 or TGF- on both articular cartilage composition and osteophyte formation10.1053/joca.1998.0129 ↗
35. Van den Berg WB, van der Kraan PM, van Beuningen HM. Growth factors and cartilage repair in OA. In: Reginster JY, Pelltier JP, Martel-Pelletier J, Henrotin Y, editors. Osteoarthritis. Clinical and experimental aspects. Berlin: Springer-Verlag; 1999. p. 185–207.10.1007/978-3-642-60026-5_10 ↗
36. Overexpression of active TGF β1 in the murine knee joint. Evidence for synovial layer dependent chondro-osteophyte formation10.1053/joca.2000.0368 ↗
37. Inhibition of endogenous TGF-β during experimental osteoarthritis prevents osteophyte formation and impairs cartilage repair10.4049/jimmunol.169.1.507 ↗
38. Adenoviral-mediated gene tranfer to rabbit synovium in vivo10.1172/JCI116614 ↗
39. A tropism modified adenoviral vector increased the effectivity of gene therapy for arthritis10.1038/sj.gt.3301612 ↗
40. Insertion of an RGD motif into the H1 loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administerd vector10.1038/sj.gt.3300941 ↗
41. Succesful genetic transduction in vivo into synovium by means of electroporation10.1016/S0006-291X(02)00386-8 ↗
42. The impact of protein size and charge on its retention in articular cartilage
43. In vivo direct gene transfer into articular cartilage by intraarticular injection mediated by HVJ (Sendai virus) and liposomes10.1002/art.1780400518 ↗
44. Empirical advantages of adeno associated viral vectors in viv gene therapy fro arthritis
45. Light-activated gene transduction enhances adeno-assocated virus vector-mediated gene expression in human articular chondrocytes10.1002/art.10433 ↗
46. Transplantation of adenovirally transduced allogenic chondrocytes into cartilage defects in vivo10.1016/S1063-4584(97)80023-4 ↗
47. Intraarticular expression of biologically active interleukin-1-receptor-antagonist protein by ex vivo gene transfer10.1073/pnas.90.22.10764 ↗
48. Gene therapy in arthritis10.2169/internalmedicine.38.233 ↗
49. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects10.1073/pnas.95.8.4613 ↗
50. Suppression of collagen-induced arthritis through adenovirus-mediated transfer of amodified tumor necrosis factor alpha receptor gene10.1002/art.1780400916 ↗
51. IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis10.4049/jimmunol.166.2.1214 ↗
52. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-410.4049/jimmunol.166.5.3499 ↗
53. Gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion10.1172/JCI7739 ↗
54. Intra-articular IL-4 gene therapy in arthritis10.1038/sj.gt.3301049 ↗
55. Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis10.4049/jimmunol.160.11.5213 ↗
56. Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer10.4049/jimmunol.161.3.1516 ↗
57. Stem cells for repair of cartilage and bone10.1136/ard.60.4.305 ↗
58. The impact of mammalian gene regulation concepts on functional geneomic research, metabolic engineering, and advanced gene therapies10.1021/bp000129c ↗
59. The transcription factors L-Sox5 and Sox6 are essential for cartilage formation10.1016/S1534-5807(01)00003-X ↗